REpeated AutoLogous Infusions of STem cells in Cirrhosis (REALISTIC): A multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  King, A ^a,b   Barton, D ^a   Beard, H A ^a,c   Than, N ^a   Moore, J ^d   Corbett, C ^a   Thomas, J ^d   Guo, K ^a   Guha, I ^e   Hollyman, D ^c   Stocken, D ^f   Yap, C ^a   Fox, R ^a   Forbes, S J ^d   Newsome, P N ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; LENOGRASTIM; URSODEOXYCHOLIC ACID; GLYCOPROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; PEPTIDE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY WEIGHT; CELL ISOLATION; CLINICAL PROTOCOL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE SEVERITY; EFFECT SIZE; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTHESIS; INFUSION; LEUKAPHERESIS; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; OPEN STUDY; PATIENT SAFETY; PERIPHERAL VEIN; PHASE 2 CLINICAL TRIAL; PRIMARY BILIARY CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME; ADOLESCENT; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; BONE MARROW; CHEMISTRY; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; STEM CELL MOBILIZATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BONE MARROW; CELL- AND TISSUE-BASED THERAPY; GLYCOPROTEINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; MIDDLE AGED; PEPTIDES; RECOMBINANT PROTEINS; RESEARCH DESIGN; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84926471980     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007700     Document Type: Article

References (40)

1. Chief Medical Officer Annual Report (United Kingdom). 2012.
2. NHSBT Liver Transplantation Activity Report (United Kingdom). 2012.
3. Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 2008;135:438-50.
4. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999;284:1168-70.
5. Theise ND, Badve S, Saxena R, et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 2000;31:235-40.
6. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000;6:1229-34.
7. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304-11.
8. Yannaki E, Athanasiou E, Xagorari A, et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol 2005;33:108-19.
9. Quintanilha LF, Mannheimer EG, Carvalho AB, et al. Bone marrow cell transplant does not prevent or reverse murine liver cirrhosis. Cell Transplant 2008;17:943-53.
10. Thomas JA, Pope C, Wojtacha D, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011;53:2003-15.
11. am Esch JS, Schmelzle M, Fürst G, et al. Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study. Ann Surg 2012;255:79-85.
12. am Esch JS II, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-70.
13. Furst G, Schulte am Esch J, Poll LW, et al. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 2007;243:171-9.
14. Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol 2012;56:496-9.
15. Gordon MY, Levicar N, Pai M, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 2006;24:1822-30.
16. Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006;24:2292-8.
17. Lyra AC, Soares MB, da Silva LF, et al. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol 2007;13:1067-73.
18. Lyra AC, Soares MB, da Silva LF, et al. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol 2010;22:33-42.
19. Ismail A, Fouad O, Abdelnasser A, et al. Stem cell therapy improves the outcome of liver resection in cirrhotics. J Gastrointest Cancer 2010;41:17-23.
20. Moore JK, Stutchfield BM, Forbes SJ, et al. Systematic review: the effects of autologous stem cell therapy for patients with liver disease. Aliment Pharmacol Ther 2014;39:673-85.
21. Spahr L, Chalandon Y, Terraz S, et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS ONE 2013;8:e53719.
22. Gordon PR, Leimig T, Babarin-Dorner A, et al. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant 2003;31:17-22.
23. Bornhauser M, Eger L, Oelschlaegel U, et al. Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia 2005;19:161-5.
24. Lorenzini S, Isidori A, Catani L, et al. Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther 2008;27:932-9.
25. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71.
26. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
27. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
28. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.
29. Huo TI, Wu JC, Lin HC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826-32.
30. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-13.
31. Bambha K, Kim WR, Kremers WK, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004;4:1798-804.
32. Choi PC, Kim HJ, Choi WH, et al. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver Int 2009;29:221-6.
33. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73.
34. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
35. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
36. Barber K, Madden S, Allen J, et al. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011;92:469-76.
37. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26.
38. Salama H, Zekri AR, Zern M, et al. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. Cell Transplant 2010;19:1475-86.
39. Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 2007;13:3359-63.
40. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.